Personalis’ NeXT Personal test shows predictive efficacy in breast cancer

Personalis (PSNL) announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article showed that ultrasensitive molecular residual disease – MRD – testing with NeXT Personal can perform better than current standard approaches in predicting patient outcomes following neoadjuvant therapy, or NAT. The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer. The results demonstrate the ability of NeXT Personal to provide a more precise risk-stratification for patients who have received NAT. A key finding of the study was the necessity of the ultrasensitive range for accurately tracking patient response to neoadjuvant therapy. Detectable ctDNA post-NAT was associated with a 4 to 9 times higher likelihood of relapse. Patients with detectable ctDNA up to 12 months post-surgery were more than 100 times more likely to experience disease recurrence. The findings reinforce the NeXT Personal test’s ability to detect ctDNA at ultrasensitive levels, providing a window for earlier clinical intervention that other approaches may miss.